Lorrin M. Koran

Prof. Dr. Lorrin M. Koran

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in CNS Spectrums
Verified
Journal Article
Closed access
PDF file
LKLorrin M. Koran
Lorrin M. Koran
EAElias Abujaoude
Elias Abujaoude
MLMichael D. Large
Michael D. Large
RSRichard T. Serpe
Richard T. Serpe
Objective:: In clinical samples, body dysmorphic disorder (BDD) is associated with substantial suffering and reduced quality of life. Limited surveys report widely varying prevalence estimates. To better establish the prevalence of BDD, we conducted a United States nationwide prevalence survey.Method:: We conducted a random sample national household telephone survey in the spring and summer of 2004 and interviewed 2,513 adults, of whom 2,048 qualified for the BDD-module administration. The computer-assisted, structured interviews, conducted by trained lay interviewers, addressed Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for BDD, along with information regarding several impulse-control disorders and the respondents' financial and demographic data.Results:: The rate of response was 56.3%, which compared favorably with rates in federal national health surveys. The cooperation rate was 97.6%. Respondents included a higher percentage of women and people >55 years of age than in the US adult population, and a lower percentage of Hispanics. The estimated point prevalence of DSM-IV BDD among respondents was 2.4% (49/2,048) (by gender: 2.5% for women, 2.2% for men), exceeding the prevalence of schizophrenia and bipolar disorder type I and about that of generalized anxiety disorder. BDD prevalence decreased after 44 years of age, and a larger proportion of BDD respondents were never married. Of those meeting DSM-IV criteria for BDD, 90% (45/49) met the DSM-IV distress criterion, and 51% (25/49) met the interference-with-functioning criterion.Conclusion:: A study using clinically valid interviews is needed to evaluate these results. Such studies could inform treatment by documenting rates of seeking treatment from various sources, suicide attempt rates, and the prevalence of comorbid conditions.

1 July 2007
Verified
Journal Article
Closed access
LKLorrin M. Koran
Lorrin M. Koran
GHGregory Hanna
Gregory Hanna
EHEric Hollander
Eric Hollander
GNGerald Nestadt
Gerald Nestadt
HSHelen Blair Simpson
Helen Blair Simpson
AAAmerican Psychiatric Association
American Psychiatric Association

1 January 2002 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
LKLorrin M. Koran
Lorrin M. Koran
EHElizabeth Hackett
Elizabeth Hackett
ARArkady Rubin
Arkady Rubin
RWRobert Wolkow
Robert Wolkow
DRDelbert Robinson
Delbert Robinson

15 July 2000 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
LKLorrin M. Koran
Lorrin M. Koran
ARAlan L. Ringold
Alan L. Ringold
MEMichael A. Elliott
Michael A. Elliott
Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD). Since olanzapine and risperidone have similar serotonergic and dopaminergic receptor binding profiles, we tested the hypothesis that olanzapine augmentation would be beneficial in treatment-unresponsive OCD.

15 March 2005 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
LKLorrin M. Koran
Lorrin M. Koran
EAElias Aboujaoude
Elias Aboujaoude
KBKim D. Bullock
Kim D. Bullock
BFBettina Franz
Bettina Franz
NGNona Gamel
Nona Gamel
MEMichael Elliott
Michael Elliott
Obsessive-compulsive disorder (OCD) often responds inadequately to serotonin reuptake inhibitors (SRIs). A case series reported substantial response to once-weekly oral morphine. We conducted a placebo-controlled, double-blind trial to investigate whether once-weekly oral morphine is effective in SRI-resistant OCD. Subjects with DSM-IV-defined OCD for > or =3 years who had failed > or =2 adequate SRI trials and had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of > or =20 were recruited. Current medications were continued. Subjects were randomly assigned to random-order, 2-week blocks of once-weekly morphine, lorazepam, and placebo. Week 2 dosage was increased, decreased, or maintained depending on response and side effects. We enrolled 23 subjects, who had failed 2 to 6 SRI trials. The median screening Y-BOCS score was 29. The median Y-BOCS score after morphine (highest dose) was 25 (median decrease = 13%). Seven subjects (30%) were responders (Y-BOCS decreases > or =25%). The median Y-BOCS score after lorazepam (highest dose) was 27 (median decrease = 6%). Four subjects (17%) responded to lorazepam; 1 was a morphine responder. The median Y-BOCS score after placebo (highest dose) was 27 (median decrease = 7%), and no subject responded. Responses differed significantly among the 3 conditions (Friedman 2-way analysis of variance, chir(2) = 13.92, df = 2, p = .01). Wilcoxon matched-pairs signed-rank tests (T = 56.5, p = .05) showed significance for morphine versus placebo but not lorazepam versus placebo. Our results support the hypothesis that once-weekly oral morphine can reduce symptoms in some treatment-resistant OCD patients. The mechanism of action is unknown. Further studies of mu-agonists and glutamate antagonists are warranted.

1 October 2006 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
LKLorrin M. Koran
Lorrin M. Koran
RFRonald Faber
Ronald Faber
EAElias Aboujaoude
Elias Aboujaoude
MLMichael Large
Michael Large
RSRichard Serpe
Richard Serpe